2021 | Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study | Harbeck, N; Rastogi, P; Martin, M; Tolaney, S M; Shao, Z M; Fasching, P A; CHIUN-SHENG HUANG ; Jaliffe, G G; Tryakin, A; Goetz, M P; Rugo, H S; Senkus, E; Testa, L; Andersson, M; Tamura, K; Del Mastro, L; Steger, G G; Kreipe, H; Hegg, R; Sohn, J; Guarneri, V; Cortés, J; Hamilton, E; André, V; Wei, R; Barriga, S; Sherwood, S; Forrester, T; Munoz, M; Shahir, A; San Antonio, B; Nabinger, S C; Toi, M; Johnston, S R D; O'Shaughnessy, J | Annals of oncology : official journal of the European Society for Medical Oncology | 206 | 186 | |
2022 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer | Geyer, C E; Garber, J E; Gelber, R D; Yothers, G; Taboada, M; Ross, L; Rastogi, P; CHIUN-SHENG HUANG ; et al., | Annals of oncology : official journal of the European Society for Medical Oncology | 128 | 67 | |